pioglitazone has been researched along with Aging in 26 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| "5 kg/m(2)) were randomly assigned to one of four intervention groups: pioglitazone or placebo and resistance training (RT) or no RT, while undergoing intentional weight loss via a hypocaloric diet." | 9.17 | Resistance training and pioglitazone lead to improvements in muscle power during voluntary weight loss in older adults. ( Carr, JJ; Isom, S; Kritchevsky, SB; Lyles, MF; Marsh, AP; Miller, GD; Miller, ME; Nicklas, BJ; Shea, MK; Vance Locke, RM, 2013) |
| "To compare bladder cancer incidence between patients initiating pioglitazone treatment and patients initiating treatment with dipeptidyl-peptidase-4 inhibitors [DPP-4s] or sulfonylureas." | 7.88 | Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes. ( Buse, JB; Garry, EM; Lund, JL; Pate, V; Stürmer, T, 2018) |
| "We used the F344 rat model of aging, and monitored behavioral, electrophysiological, and molecular variables to assess the effects of pioglitazone (PIO-Actos(R) a TZD) on several peripheral (blood and liver) and central (hippocampal) biomarkers of aging." | 7.76 | Effects of long-term pioglitazone treatment on peripheral and central markers of aging. ( Anderson, KL; Avdiushko, MG; Blalock, EM; Chen, KC; Cohen, DA; Gant, JC; Pancani, T; Phelps, JT; Popovic, J; Porter, NM; Searcy, JL; Thibault, O, 2010) |
| " Here, we found that the PPAR-gamma agonist pioglitazone protected against renal injury in aging; it reduced proteinuria, improved GFR, decreased sclerosis, and alleviated cell senescence." | 7.75 | The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. ( Deleuze, S; Fogo, AB; Ma, LJ; Potthoff, SA; Yang, HC; Zuo, Y, 2009) |
| " The current study was designed to test the hypothesis that prolonged treatment of aging LY mice with the TZD, pioglitazone, alters the ovarian expression of genes that may impact reproduction." | 7.74 | Pioglitazone administration alters ovarian gene expression in aging obese lethal yellow mice. ( Brannian, JD; Diggins, M; Eyster, KM; Weber, M, 2008) |
| "Pioglitazone treatment significantly increased phosphorylated (p-) Akt but significantly reduced p-ERK1/2 and p-JNK." | 5.38 | PPAR-γ activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model. ( Aonuma, K; Hirayama, A; Igarashi, M; Ito, Y; Murakoshi, N; Seo, Y; Tada, H; Xu, D, 2012) |
| "5 kg/m(2)) were randomly assigned to one of four intervention groups: pioglitazone or placebo and resistance training (RT) or no RT, while undergoing intentional weight loss via a hypocaloric diet." | 5.17 | Resistance training and pioglitazone lead to improvements in muscle power during voluntary weight loss in older adults. ( Carr, JJ; Isom, S; Kritchevsky, SB; Lyles, MF; Marsh, AP; Miller, GD; Miller, ME; Nicklas, BJ; Shea, MK; Vance Locke, RM, 2013) |
| "To compare bladder cancer incidence between patients initiating pioglitazone treatment and patients initiating treatment with dipeptidyl-peptidase-4 inhibitors [DPP-4s] or sulfonylureas." | 3.88 | Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes. ( Buse, JB; Garry, EM; Lund, JL; Pate, V; Stürmer, T, 2018) |
| "We used the F344 rat model of aging, and monitored behavioral, electrophysiological, and molecular variables to assess the effects of pioglitazone (PIO-Actos(R) a TZD) on several peripheral (blood and liver) and central (hippocampal) biomarkers of aging." | 3.76 | Effects of long-term pioglitazone treatment on peripheral and central markers of aging. ( Anderson, KL; Avdiushko, MG; Blalock, EM; Chen, KC; Cohen, DA; Gant, JC; Pancani, T; Phelps, JT; Popovic, J; Porter, NM; Searcy, JL; Thibault, O, 2010) |
| " Here, we found that the PPAR-gamma agonist pioglitazone protected against renal injury in aging; it reduced proteinuria, improved GFR, decreased sclerosis, and alleviated cell senescence." | 3.75 | The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury. ( Deleuze, S; Fogo, AB; Ma, LJ; Potthoff, SA; Yang, HC; Zuo, Y, 2009) |
| " The current study was designed to test the hypothesis that prolonged treatment of aging LY mice with the TZD, pioglitazone, alters the ovarian expression of genes that may impact reproduction." | 3.74 | Pioglitazone administration alters ovarian gene expression in aging obese lethal yellow mice. ( Brannian, JD; Diggins, M; Eyster, KM; Weber, M, 2008) |
| "The role of insulin resistance in the impaired glucose-stimulated insulin release of Zucker fatty rats was investigated using the insulin-sensitizing thiazolidinedione drug pioglitazone." | 3.69 | Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance. ( de Souza, CJ; Meglasson, MD; Robinson, DD; Ulrich, RG; Yu, JH, 1995) |
| "Pioglitazone treatment in adult BHR caused no detectable changes in antioxidant and detoxificant responses." | 1.51 | Age-dependent effect of PPARγ agonist pioglitazone on kidney signaling in borderline hypertensive rats. ( Dovinova, I; Grešová, L; Kvandova, M; Kvasnicka, P, 2019) |
| "The elderly patients with type 2 diabetes suffer more adverse drug events than young adults due to pharmacokinetic and pharmacodynamic changes associated with aging." | 1.48 | Benefits of combination low-dose pioglitazone plus fish oil on aged type 2 diabetes mice. ( Chiba, K; Hirako, S; Iizuka, Y; Kim, H; Matsumoto, A; Wada, M, 2018) |
| "Pioglitazone treatment significantly increased phosphorylated (p-) Akt but significantly reduced p-ERK1/2 and p-JNK." | 1.38 | PPAR-γ activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model. ( Aonuma, K; Hirayama, A; Igarashi, M; Ito, Y; Murakoshi, N; Seo, Y; Tada, H; Xu, D, 2012) |
| "Glyburide did not lower DPP-IV activity or glycosylated hemoglobin." | 1.32 | Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments. ( Croom, DK; Lenhard, JM; Minnick, DT, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (7.69) | 18.2507 |
| 2000's | 8 (30.77) | 29.6817 |
| 2010's | 16 (61.54) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barger, JL | 1 |
| Vann, JM | 1 |
| Cray, NL | 1 |
| Pugh, TD | 1 |
| Mastaloudis, A | 1 |
| Hester, SN | 1 |
| Wood, SM | 1 |
| Newton, MA | 1 |
| Weindruch, R | 1 |
| Prolla, TA | 1 |
| Garry, EM | 1 |
| Buse, JB | 1 |
| Lund, JL | 1 |
| Pate, V | 1 |
| Stürmer, T | 1 |
| Shen, D | 1 |
| Li, H | 1 |
| Zhou, R | 1 |
| Liu, MJ | 1 |
| Yu, H | 1 |
| Wu, DF | 1 |
| Chang, L | 1 |
| Zhao, X | 1 |
| Garcia-Barrio, M | 1 |
| Zhang, J | 1 |
| Eugene Chen, Y | 1 |
| Iizuka, Y | 1 |
| Kim, H | 1 |
| Hirako, S | 1 |
| Chiba, K | 1 |
| Wada, M | 1 |
| Matsumoto, A | 1 |
| Nakashima, M | 1 |
| Kinoshita, M | 1 |
| Nakashima, H | 1 |
| Kotani, A | 1 |
| Ishikiriyama, T | 1 |
| Kato, S | 1 |
| Hiroi, S | 1 |
| Seki, S | 1 |
| Grešová, L | 1 |
| Kvandova, M | 1 |
| Kvasnicka, P | 1 |
| Dovinova, I | 1 |
| Prakash, A | 1 |
| Kumar, A | 1 |
| Abdel-Rahman, EM | 1 |
| Okusa, MD | 1 |
| Wang, P | 1 |
| Li, B | 1 |
| Cai, G | 1 |
| Huang, M | 1 |
| Jiang, L | 1 |
| Pu, J | 1 |
| Li, L | 1 |
| Wu, Q | 1 |
| Zuo, L | 1 |
| Wang, Q | 1 |
| Zhou, P | 1 |
| Zhang, Z | 1 |
| Yuan, H | 1 |
| Zhao, H | 1 |
| Qi, B | 1 |
| Li, F | 1 |
| An, L | 1 |
| Nicolakakis, N | 2 |
| Aboulkassim, T | 2 |
| Ongali, B | 1 |
| Lecrux, C | 1 |
| Fernandes, P | 1 |
| Rosa-Neto, P | 2 |
| Tong, XK | 2 |
| Hamel, E | 2 |
| Akiyama, M | 1 |
| Hatanaka, M | 1 |
| Ohta, Y | 1 |
| Ueda, K | 1 |
| Yanai, A | 1 |
| Uehara, Y | 1 |
| Tanabe, K | 1 |
| Tsuru, M | 1 |
| Miyazaki, M | 1 |
| Saeki, S | 1 |
| Saito, T | 1 |
| Shinoda, K | 1 |
| Oka, Y | 1 |
| Tanizawa, Y | 1 |
| Yang, HC | 1 |
| Deleuze, S | 1 |
| Zuo, Y | 1 |
| Potthoff, SA | 1 |
| Ma, LJ | 1 |
| Fogo, AB | 1 |
| Blalock, EM | 1 |
| Phelps, JT | 1 |
| Pancani, T | 1 |
| Searcy, JL | 1 |
| Anderson, KL | 1 |
| Gant, JC | 1 |
| Popovic, J | 1 |
| Avdiushko, MG | 1 |
| Cohen, DA | 1 |
| Chen, KC | 1 |
| Porter, NM | 1 |
| Thibault, O | 1 |
| Aliaga, A | 1 |
| Spyridopoulos, I | 1 |
| Xu, D | 1 |
| Murakoshi, N | 1 |
| Igarashi, M | 1 |
| Hirayama, A | 1 |
| Ito, Y | 1 |
| Seo, Y | 1 |
| Tada, H | 1 |
| Aonuma, K | 1 |
| Marsh, AP | 1 |
| Shea, MK | 1 |
| Vance Locke, RM | 1 |
| Miller, ME | 1 |
| Isom, S | 1 |
| Miller, GD | 1 |
| Nicklas, BJ | 1 |
| Lyles, MF | 1 |
| Carr, JJ | 1 |
| Kritchevsky, SB | 1 |
| Takeda, K | 1 |
| Toda, K | 1 |
| Saibara, T | 1 |
| Nakagawa, M | 1 |
| Saika, K | 1 |
| Onishi, T | 1 |
| Sugiura, T | 1 |
| Shizuta, Y | 1 |
| Lenhard, JM | 1 |
| Croom, DK | 1 |
| Minnick, DT | 1 |
| Pathan, AR | 1 |
| Viswanad, B | 1 |
| Sonkusare, SK | 1 |
| Ramarao, P | 1 |
| Brannian, JD | 1 |
| Eyster, KM | 1 |
| Weber, M | 1 |
| Diggins, M | 1 |
| Szöcs, Z | 1 |
| Brunmair, B | 1 |
| Stadlbauer, K | 1 |
| Nowotny, P | 1 |
| Bauer, L | 1 |
| Luger, A | 1 |
| Fürnsinn, C | 1 |
| de Souza, CJ | 1 |
| Yu, JH | 1 |
| Robinson, DD | 1 |
| Ulrich, RG | 1 |
| Meglasson, MD | 1 |
| Umeda, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cerebrovascular Reactivity (CVR) Assessed With Functional Near Infrared Spectroscopy (fNIRS) as a Biomarker of Traumatic Cerebrovascular Injury (TCVI) Measured Longitudinally After Acute TBI in Military Personnel[NCT04058132] | Phase 2 | 50 participants (Anticipated) | Interventional | 2019-08-09 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for pioglitazone and Aging
| Article | Year |
|---|---|
Effects of aging on renal function and regenerative capacity.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Aging; Animals; Cellular Senescence; Disease Models, A | 2014 |
Potential role of thiazolidinediones in older diabetic patients.
Topics: Aged; Aging; Animals; Benzopyrans; Chromans; Diabetes Mellitus, Type 2; Double-Blind Method; Glucose | 1995 |
1 trial available for pioglitazone and Aging
| Article | Year |
|---|---|
Resistance training and pioglitazone lead to improvements in muscle power during voluntary weight loss in older adults.
Topics: Aged; Aging; Body Composition; Body Mass Index; Female; Follow-Up Studies; Humans; Hypoglycemic Agen | 2013 |
23 other studies available for pioglitazone and Aging
| Article | Year |
|---|---|
Identification of tissue-specific transcriptional markers of caloric restriction in the mouse and their use to evaluate caloric restriction mimetics.
Topics: 2,4-Dinitrophenol; Adipose Tissue, White; Aging; Animals; Bezafibrate; Caloric Restriction; Carnitin | 2017 |
Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Aging; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV I | 2018 |
Pioglitazone attenuates aging-related disorders in aged apolipoprotein E deficient mice.
Topics: Age Factors; Aging; Animals; Anti-Inflammatory Agents; Antioxidants; Aortic Diseases; Atherosclerosi | 2018 |
MitoNEET in Perivascular Adipose Tissue Prevents Arterial Stiffness in Aging Mice.
Topics: Adipose Tissue, Brown; Adiposity; Age Factors; Aging; Animals; Cardiovascular Diseases; Diet, High-F | 2018 |
Benefits of combination low-dose pioglitazone plus fish oil on aged type 2 diabetes mice.
Topics: Aging; Animals; Diabetes Mellitus, Type 2; Docosahexaenoic Acids; Drug Therapy, Combination; Eicosap | 2018 |
Pioglitazone improves phagocytic activity of liver recruited macrophages in elderly mice possibly by promoting glucose catabolism.
Topics: Aging; Animals; CD11b Antigen; Cytokines; Escherichia coli; Escherichia coli Infections; Glucose; In | 2019 |
Age-dependent effect of PPARγ agonist pioglitazone on kidney signaling in borderline hypertensive rats.
Topics: Aging; Animals; Hypertension; Kidney; Pioglitazone; PPAR gamma; Rats | 2019 |
Pioglitazone alleviates the mitochondrial apoptotic pathway and mito-oxidative damage in the d-galactose-induced mouse model.
Topics: Acetylcholinesterase; Aging; Animals; Antioxidants; Apoptosis; Behavior, Animal; Brain; Caspase 3; C | 2013 |
Activation of PPAR-γ by pioglitazone attenuates oxidative stress in aging rat cerebral arteries through upregulating UCP2.
Topics: Aging; Animals; Cerebral Arteries; Human Umbilical Vein Endothelial Cells; Humans; Ion Channels; Mal | 2014 |
PPARγ activation ameliorates postoperative cognitive decline probably through suppressing hippocampal neuroinflammation in aged mice.
Topics: Aging; Anilides; Animals; Brain-Derived Neurotrophic Factor; Cells, Cultured; Cognitive Dysfunction; | 2017 |
Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist.
Topics: Acetylcholine; Acetylcysteine; Aging; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein | 2008 |
Increased insulin demand promotes while pioglitazone prevents pancreatic beta cell apoptosis in Wfs1 knockout mice.
Topics: Aging; Animals; Apoptosis; Body Weight; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; | 2009 |
The PPARgamma agonist pioglitazone ameliorates aging-related progressive renal injury.
Topics: Age Factors; Aging; Animals; Disease Progression; Kidney Diseases; Male; Pioglitazone; PPAR gamma; R | 2009 |
Effects of long-term pioglitazone treatment on peripheral and central markers of aging.
Topics: Aging; Alzheimer Disease; Animals; Biomarkers; Brain; Hippocampus; Hypoglycemic Agents; Inflammation | 2010 |
Intact memory in TGF-β1 transgenic mice featuring chronic cerebrovascular deficit: recovery with pioglitazone.
Topics: Aging; Animals; Antioxidants; Blotting, Western; Cerebrovascular Circulation; Cerebrovascular Disord | 2011 |
Is telomerase a potential target for vascular rejuvenation?
Topics: Aging; Animals; Aorta; Apoptosis; Cellular Senescence; Cytoprotection; Endothelial Cells; Enzyme Act | 2011 |
PPAR-γ activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model.
Topics: Aging; Animals; Antioxidants; Apoptosis; Atrial Fibrillation; Cardiotonic Agents; Disease Models, An | 2012 |
Progressive development of insulin resistance phenotype in male mice with complete aromatase (CYP19) deficiency.
Topics: Aging; Animals; Aromatase; Bezafibrate; Blood Glucose; Cholesterol; Estradiol; Glucose Tolerance Tes | 2003 |
Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments.
Topics: Aging; Animals; Blood Glucose; Cell Membrane; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptid | 2004 |
Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats.
Topics: Administration, Oral; Aging; Animals; Antibiotics, Antineoplastic; Brain Chemistry; Cognition; Demen | 2006 |
Pioglitazone administration alters ovarian gene expression in aging obese lethal yellow mice.
Topics: Administration, Oral; Aging; Animals; Female; Gene Expression; Gene Expression Profiling; Intercellu | 2008 |
Age-dependent development of metabolic derangement and effects of intervention with pioglitazone in Zucker diabetic fatty rats.
Topics: Aging; Animals; Blood Glucose; Body Weight; Diabetes Mellitus; Pioglitazone; Rats; Rats, Zucker; Thi | 2008 |
Insulin secretory defect in Zucker fa/fa rats is improved by ameliorating insulin resistance.
Topics: Aging; Amino Acids; Animals; Blood Glucose; Fatty Acids, Nonesterified; Female; Glucose; Hypoglycemi | 1995 |